Anthera Pharmaceuticals Inc news

   Watch this stock
Showing stories 1 - 10 of about 88   

Articles published

ANTH 5.88 +0.68 (13.08%)
price chart
Anthera Pharmaceuticals, Inc. Short Interest Update
Anthera Pharmaceuticals, Inc. (NASDAQ:ANTH) has shown a drop of 2.1% or 56,229 shares in the short positions. The bets have increased to 2,614,439 shares on November 13,2015 from 2,670,668 shares on October 30,2015.
Anthera Pharmaceuticals Inc Stock Price Increases Today
Recent Investment Analysts' Ratings Changes for Anthera Pharmaceuticals ...  Dakota Financial News
Zacks Investment Research Downgrades Anthera Pharmaceuticals to Sell (ANTH)
According to Zacks, “Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing products to treat serious illnesses, including cardiovascular and autoimmune diseases.
Company Shares of Anthera Pharmaceuticals, Inc. (NASDAQ:ANTH) Drops by -0.19%
Anthera Pharmaceuticals, Inc. (NASDAQ:ANTH) has lost 0.19% during the past week and dropped 9.57% in the last 4 weeks.
Colin Hislop, Chief Medical Officer of Anthera Pharmaceuticals Inc (NASDAQ ...
Mid-Day Market Update: HP Slides Following Q4 Results; Deere Shares Surge
Meanwhile, top gainers in the sector included Anthera Pharmaceuticals Inc (NASDAQ: ANTH), up 12 percent, and Zogenix, Inc. (NASDAQ: ZGNX), up 10 percent.
Price Target Update on Anthera Pharmaceuticals, Inc. (NASDAQ:ANTH)
Anthera Pharmaceuticals, Inc. (NASDAQ:ANTH): According to 3 Analysts, The short term target price has been estimated at $ 13.33.
Anthera Pharmaceuticals Trading Down 4.7% After Insider Selling (ANTH)  WKRB News
Anthera Pharmaceuticals Trading Down 4.7% Following Insider Selling (ANTH)  Dakota Financial News
Why Anthera Pharmaceuticals, Inc. Shares Are Soaring Higher
What: Shares in Anthera Pharmaceuticals, Inc. (NASDAQ:ANTH) jumped by 10% earlier today after the company announced after the bell yesterday that it would present updated data from its phase 2b study evaluating blisibimod as a treatment for lupus at an ...
Anthera Pharmaceuticals, Inc. Price Target Update
Anthera Pharmaceuticals, Inc. (NASDAQ:ANTH) shares are expected to touch $13.33 in the short term. This short term price target has been shared by 3 analysts.
Company Shares of Anthera Pharmaceuticals, Inc. (NASDAQ:ANTH) Drops by -12.83%  American Trade Journal
Anthera Pharmaceuticals insider Colin Hislop Sells 5000 Shares (ANTH)  MidSouth Newz
Zacks Short Term Rating on Anthera Pharmaceuticals, Inc. (NASDAQ:ANTH)
Anthera Pharmaceuticals, Inc. (NASDAQ:ANTH) has received a short term rating of hold from research analysts at Zacks with a rank of 3. The company has been rated an average of 1 by 3 Wall Street Analysts.
Technical and Fundamental Insights on Anthera Pharmaceuticals Inc (NASDAQ:ANTH)  Street Report
Anthera Pharmaceuticals Lifted to Buy at Zacks (ANTH)  MidSouth Newz
Stocks With Impressive Top Line Growth And Liquidity: Anthera Pharmaceuticals ...
Interested in gaining exposure to services companies? Company liquidity is an important consideration in any stock analysis.
Colin Hislop, Anthera Pharmaceuticals Inc (NASDAQ:ANTH)'s insider Unloaded ...
An insider Colin Hislop who is Chief Medical Officer of Anthera Pharmaceuticals Inc (NASDAQ:ANTH) 5.30 +0.14 2.71% unloaded some 5,000 shares of the public company having a value near $26,900 USD based on an avg price of $5.4 per share.